Maldives vs United States: The number of people with susceptibility test result for rifampicin
Maldives
95.83
in 2021
United States
94.32
in 2021
Maldives rank
50th
United States rank
53rd
The number of people with susceptibility test result for rifampicin over time
- Maldives
- United States
How they compare
Maldives currently reports 95.83 against 94.32 in United States, a difference of 1.51.
The two have swapped places 3 times across 5 shared years of data; in 2017 it was United States ahead.
Maldives ranks 50th and United States ranks 53rd of 146 countries.
United States has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Maldives | United States | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 71.76 | 90.97 | 19.21 | United States |
| 2020s | 79.08 | 94.51 | 15.44 | United States |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Maldives or United States?
- Maldives, at 95.83 against 94.32 in United States as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Maldives and United States?
- 1.51, with Maldives ahead.
- How many years of comparable data are there for Maldives and United States?
- 5 years are reported by both, from 2017 to 2021.
- How do Maldives and United States rank globally for the number of people with susceptibility test result for rifampicin?
- Maldives ranks 50th and United States ranks 53rd of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.